Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 4/20 | 0.59 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5964114 | 0.80 | CNR2 (0.64) | PRMT1CNR2KDM4EALDH1A1SLC9A1 | |
| SCHEMBL5964602 | 0.78 | MEN1 (0.46) | PRMT1CNR2CYP2C19KDM4EALDH1A1 | |
| SCHEMBL5963771 | 0.78 | MEN1 (0.46) | PRMT1CNR2KDM4EALDH1A1MEN1 | |
| SCHEMBL30034816 | 0.77 | CNR2 (0.58) | CNR2KDM4EALDH1A1PNMTTAAR1 | |
| SCHEMBL30353293 | 0.77 | CNR2 (0.58) | CNR2KDM4EALDH1A1PNMTTAAR1 | |
| SCHEMBL22817597 | 0.77 | CNR2 (0.58) | CNR2KDM4EALDH1A1PNMTTAAR1 | |
| SCHEMBL22817603 | 0.77 | CNR2 (0.58) | CNR2KDM4EALDH1A1PNMTTAAR1 | |
| SCHEMBL22817596 | 0.77 | CNR2 (0.58) | CNR2KDM4EALDH1A1PNMTTAAR1 | |
| SCHEMBL12519881 | 0.71 | PRMT1 (0.57) | PRMT1CYP1A2CYP2C19KDM4EALDH1A1 | |
| SCHEMBL1198267 | 0.71 | KDM4E (0.59) | PRMT1CYP1A2CYP2C19KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052315-A1 | Cb 1/cb 2 receptor ligands and their use in the treatment of pain | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | claimed |
| EP-1594856-A1 | CB 1/CB 2 RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2005-11-16 | — | — | EP | claimed |
| WO-2004060882-A1 | CB 1/CB 2 RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2004-07-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052315-A1 | Cb 1/cb 2 receptor ligands and their use in the treatment of pain | CNR1, CNR2, OPRL1 | PRMT1 3239/4885CNR2 2/4885CYP1A2 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.